Pharmacotherapy of hypertension in different patients. Why combination drugs, why the combination of telmisartan, amlodipine and hydrochlorothiazide? Review article
Article Sidebar
Published:
Oct 20, 2026
Keywords:
arterial hypertension, pharmacotherapy, combination drugs, efficacy, safety
Main Article Content
Abstract
Rational combination pharmacotherapy for hypertension is based on individualized combinations of antihypertensive drugs. Optimal treatment for hypertension should be initiated as early as possible in the course of the disease and should provide the patient with stable and long-term blood pressure control, which translates into reduced risk of cardiovascular disease and death, which are associated with complications of inadequately treated hypertension. According to current medical knowledge, one of the most optimal drug combinations used in the treatment of hypertension is telmisartan, amlodipine, and hydrochlorothiazide.
Article Details
How to Cite
Woroń, J. (2026). Pharmacotherapy of hypertension in different patients. Why combination drugs, why the combination of telmisartan, amlodipine and hydrochlorothiazide?. Medycyna Faktow (J EBM), 19(2(71), 216-220. https://doi.org/10.24292/01.MF.0226.11
Issue
Section
Articles
Copyright by Medical Education. All rights reserved.
References
1. Wright JT, Williamson J, Whelton P et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373: 2103-16. http://doi.org/10.1056/NEJMoa1511939.
2. Verma AA, Khuu W, Tadrous M et al. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: a population-based retrospective cohort study. PLoS Med. 2018; 15: e1002584. http://doi.org/10.1371/journal.pmed.1002584.
3. Salam A, Atkins ER, Hsu B et al. Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019; 37: 1567-73. http://doi.org/10.1097/HJH.0000000000002089.
4. Cidda M, Mateti UV, Batchu MK et al. Study of prescribing patterns of antihypertensives in South Indian population. Int J Basic Clin Pharmacol. 2014; 3: 303-7.
5. Michel MC, Bohner H, Koster J et al. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf. 2004; 27: 335-44.
6. Choi GJ, Kim HM, Kang H et al. Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2016; 32: 1303-9.
7. Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens. 2014; 8(5): 340-9.
8. Messerli FH, Staessen JA. Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies. Hypertension. 2006; 48(3): 359-61.
9. Wang JG, Kario K, Lau T et al. Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association. Hypertens Res. 2011; 34(4): 423-30.
10. Ernst ME, Fravel MA. Thiazide and the Thiazide-Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide. Am J Hypertens. 2022; 35(7): 573-86.
11. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71(6): e13-e115.
2. Verma AA, Khuu W, Tadrous M et al. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: a population-based retrospective cohort study. PLoS Med. 2018; 15: e1002584. http://doi.org/10.1371/journal.pmed.1002584.
3. Salam A, Atkins ER, Hsu B et al. Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019; 37: 1567-73. http://doi.org/10.1097/HJH.0000000000002089.
4. Cidda M, Mateti UV, Batchu MK et al. Study of prescribing patterns of antihypertensives in South Indian population. Int J Basic Clin Pharmacol. 2014; 3: 303-7.
5. Michel MC, Bohner H, Koster J et al. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf. 2004; 27: 335-44.
6. Choi GJ, Kim HM, Kang H et al. Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2016; 32: 1303-9.
7. Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens. 2014; 8(5): 340-9.
8. Messerli FH, Staessen JA. Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies. Hypertension. 2006; 48(3): 359-61.
9. Wang JG, Kario K, Lau T et al. Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association. Hypertens Res. 2011; 34(4): 423-30.
10. Ernst ME, Fravel MA. Thiazide and the Thiazide-Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide. Am J Hypertens. 2022; 35(7): 573-86.
11. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71(6): e13-e115.